Weight Loss: New Drug CagriSema Leads to 14% Weight Loss in Trial

Weight loss: New drug CagriSema leads to 14% weight loss in trial

An experimental combo drug from Novo Nordisk leads to more weight loss than semaglutide alone, according to late-stage trial data.

New drug CagriSema leads to 14% weight loss in trial - Health Care Today

A new 68-week trial found that weekly injections with CagriSema resulted in weight loss of up to 14.2% compared with 10.2% for semaglutide (Wegovy). CagriSema also reduced HbA1C scores on average by 1.91%-points compared with 1.76%-points for semaglutide. This new drug is a fixed-dose combination of semaglutide and cagrilintide, an amylin receptor agonist. GLP-1 medications have received a lot of publicity due in part to their use in treating o…